PMID- 16409917
OWN - NLM
STAT- MEDLINE
DCOM- 20060809
LR  - 20151119
IS  - 1087-2108 (Electronic)
IS  - 1087-2108 (Linking)
VI  - 11
IP  - 3
DP  - 2005 Dec 1
TI  - Sustained effects of low dose infliximab in combination with methotrexate in the 
      management of chronic recalcitrant psoriasis.
PG  - 21
AB  - Psoriasis is a chronic inflammatory skin disease whose pathogenesis is modulated 
      by numerous genetic and immunologic factors. During the last decade, our 
      understanding of the pathophysiology of psoriasis has significantly improved, and 
      the disease is now accepted as a T-cell mediated process. This concept has 
      dramatically altered the approach to the treatment of psoriasis. Tumor necrosis 
      factor-alpha (TNF-alpha) is one of the key chemokines in the pathophysiology of 
      psoriasis and its expression is notably increased in psoriatic plaques. 
      Infliximab is a chimeric anti-TNF-alpha monoclonal antibody that binds to both 
      transmembrane and soluble TNF-alpha with high affinity, specificity, and avidity. 
      Presented here is a severe recalcitrant case of psoriasis with sustained benefit 
      from low-dose infliximab in combination with methotrexate.
FAU - Zargari, Omid
AU  - Zargari O
AD  - Department of Dermatology, Guilan University of Medical Sciences, Rasht, Iran. 
      ozargari@iranderma.com
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20051201
PL  - United States
TA  - Dermatol Online J
JT  - Dermatology online journal
JID - 9610776
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Chronic Disease
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*administration & dosage
MH  - Infliximab
MH  - Methotrexate/*administration & dosage
MH  - Psoriasis/*drug therapy
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
EDAT- 2006/01/18 09:00
MHDA- 2006/08/10 09:00
CRDT- 2006/01/18 09:00
PHST- 2006/01/18 09:00 [pubmed]
PHST- 2006/08/10 09:00 [medline]
PHST- 2006/01/18 09:00 [entrez]
PST - epublish
SO  - Dermatol Online J. 2005 Dec 1;11(3):21.